AMP-224

DRUG2 trials

Sponsors

MedImmune LLC, National Cancer Institute (NCI)

Conditions

CancerColorectal CancerColorectal CarcinomaColorectal Neoplasms

Phase 1

Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer

CompletedNCT01352884

MedImmune LLCCancer

Start: 2011-03-31End: 2014-01-31Updated: 2016-09-05

AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer

CompletedNCT02298946

National Cancer Institute (NCI)Colorectal Cancer, Colorectal Carcinoma, Colorectal Neoplasms

Start: 2014-11-21End: 2017-03-07Updated: 2019-02-22

Related Papers

A pilot study of AMP-224, a PD-L2 Fc fusion protein, in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic colorectal cancer.

Journal of Clinical Oncology2016-02-0124 citations